

References

L-167

1. Palomaki GE, Bradley LA, Douglas MP, et al. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence based review. *Genet Med* 2009;11(1):21-34.
2. Irinotecan (Camptosar). Prescribing information. New York, NY: Pfizer, May 2010.
3. Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics. *Cancer* 2008;113:1502-10.
4. GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2014.
5. Food and Drug Administration. FDA MedWatch Camptosar (irinotecan HCl) injection Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) Updated May 2010.
6. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. U.S. Food and Drug Administration.
7. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V2.2016.
8. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working Group. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? *Genet Med*. Jan 2009;11(1):15-20.